DDInter899 DDInter714
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pralsetinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Fedratinib may lead to a major life threatening interaction when taken with Lurbinectedin